Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
- 31 July 1988
- Vol. 62 (3) , 531-533
- https://doi.org/10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b
Abstract
Plasminogen activator is a serine protease which exists in two forms, known as tissue-type plasminogen activator and urokinase-type plasminogen activator. Here, we show that urokinase-type plasminogen activator activity in primary breast carcinomas correlates with both size of tumor and number of axillary nodes with metastases. Patients with primary carcinomas containing high levels of urokinase-type plasminogen activator activity had a significantly shorter disease-free interval than patients with low levels of activity. It is concluded that urokinase-plasminogen activator may be a new prognostic marker in breast cancer.This publication has 6 references indexed in Scilit:
- Do proteases play a role in cancer invasion and metastasis?European Journal of Cancer and Clinical Oncology, 1987
- Plasminogen activators in human colorectal neoplasia.BMJ, 1986
- MULTIPLE FORMS OF PLASMINOGEN-ACTIVATOR IN HUMAN-BREAST TUMORS1985
- Plasminogen activator and cancerEuropean Journal of Cancer and Clinical Oncology, 1984
- Antibodies to plasminogen activator inhibit human tumor metastasisCell, 1983
- Cea-like material in cytosols from human breast carcinomas: Correlation with biochemical and pathologic parametersCancer, 1983